Analyst Upgrades Genomic Health | GenomeWeb

NEW YORK (GenomeWeb News) – Thomas Weisel Partners analyst Peter Lawson upgraded his rating on Genomic Health's stock from "market weight" to "overweight," citing the firm's relatively low valuation and potential upside.

Lawson said in a research note published last night that Genomic Health is trading below its broader peer group and such firms as Gen-Probe, Luminex, Cepheid, and Myriad Genetics. In addition, he said that a new colon cancer assay that is expected to be launched in early 2010 "will add significant value to current diagnostic workups."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.